Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
There are several factors to consider. Up to 1 in 3 people with major depression do not fully respond to a first antidepressant because of brain circuit differences, mismatched medication targets, inadequate dose or duration, overlapping conditions or misdiagnosis, trauma, and genetic metabolism differences.
Medically approved next steps include careful medication optimization or augmentation, interventional psychiatry such as TMS and esketamine, ECT, evidence-based psychotherapy, and targeted lifestyle support; see the complete guidance below for who each option fits, safety and monitoring details, and when urgent evaluation is needed, as these points can shape your next steps.
If you're still feeling depressed after trying medication, you're not alone. Up to 1 in 3 people with major depressive disorder don't respond fully to their first antidepressant. This is often called treatment-resistant depression (TRD).
That doesn't mean you're broken. It doesn't mean you'll never feel better. It means your brain may need a different approach — and today, we have more medically approved options than ever before, including advances in interventional psychiatry.
Let's break down why antidepressants sometimes don't work — and what you can do next.
Depression is not just a "chemical imbalance." It involves complex changes in:
Most traditional antidepressants target serotonin or related chemicals. But depression is often more complex than that.
Here are common reasons medication may not fully work:
Many antidepressants focus on serotonin. But some people's depression is driven more by:
If the medication doesn't match the biological driver, improvement may be limited.
Antidepressants typically take 4–8 weeks to show full benefit. Some people:
Medication adjustments should always be guided by a physician.
Some conditions look like depression but require different treatment:
If depression isn't improving, it's worth re-evaluating the diagnosis.
Trauma reshapes brain circuits. Medication can help, but without therapy or trauma-focused treatment, full recovery may stall.
Your liver enzymes affect how you metabolize medications. Some people break down antidepressants too quickly — others too slowly. Pharmacogenetic testing may help guide medication choices in certain cases.
Doctors typically define treatment-resistant depression as:
But "resistant" doesn't mean hopeless. It means it's time to consider new strategies — including interventional psychiatry.
Interventional psychiatry is a medical subspecialty focused on advanced, evidence-based treatments for depression and other mood disorders when standard treatments don't work.
These treatments directly target brain circuits involved in mood regulation.
They are not experimental. Many are FDA-cleared or FDA-approved and supported by strong clinical evidence.
Here are evidence-based options your doctor may discuss:
Before moving to procedures, doctors may:
Esketamine works on the glutamate system and can provide rapid symptom relief in some patients.
TMS is one of the most widely used tools in interventional psychiatry.
It uses magnetic pulses to stimulate specific brain regions involved in mood regulation.
Clinical studies show TMS can significantly improve symptoms in people who did not respond to medication.
Many patients return to work the same day after treatment.
Esketamine is an FDA-approved nasal spray for treatment-resistant depression.
It works differently than traditional antidepressants by targeting glutamate, a key neurotransmitter involved in brain plasticity.
It's not for everyone, but it can be life-changing for certain individuals.
ECT remains one of the most effective treatments for severe or life-threatening depression.
Despite stigma, modern ECT is:
It is particularly helpful for:
ECT can work when nearly everything else has failed.
Medication or procedures alone often aren't enough.
Evidence-based therapies include:
Combining therapy with interventional psychiatry treatments often produces stronger and longer-lasting results.
These are not "quick fixes," but they significantly influence brain health:
Lifestyle changes don't replace medical treatment — but they strengthen its effects.
If you've been trying different approaches but still feel stuck, it may help to get clarity on what you're experiencing. Take a few minutes to use this free AI-powered Depression symptom checker to better understand your symptoms and prepare meaningful questions before your next appointment.
It's not a diagnosis — but it can help you organize what you're feeling and guide more productive conversations with your doctor.
If you experience:
You should speak to a doctor immediately or seek emergency care. Depression can be life-threatening, and urgent help is available.
There is no weakness in seeking immediate support.
Here's what's changed in the last decade:
Depression is increasingly viewed as a disorder of brain circuitry — and we now have tools that directly target those circuits.
For many people, improvement comes not from giving up — but from changing strategy.
If you're still depressed despite treatment:
Most importantly: Speak to a doctor about your symptoms — especially if they are severe, worsening, or feel life-threatening.
If your brain hasn't responded to medication, it's not a failure. It's information.
Depression is complex. But so is modern treatment.
With advances in interventional psychiatry, many people who once felt stuck are now finding relief.
You deserve a treatment plan that works — and today, there are more medically approved paths forward than ever before.
(References)
* Obuchowicz, R., & Pychyńska, M. (2023). Mechanisms of Treatment-Resistant Depression: A Focus on Inflammatory Pathways. *Journal of Clinical Medicine*, *12*(7), 2603.
* Janczura, K., & Batura-Gabryel, H. (2022). Neurobiology of treatment-resistant depression: A current update. *Pharmacological Reports*, *74*(6), 1629-1641.
* Matus, B., & Dymecka, E. (2023). Novel Approaches to Treating Depression: Recent Advances in Pharmacotherapy. *Pharmaceuticals*, *16*(10), 1435.
* Liu, J., Zhang, C., Li, S., Wang, H., Lu, Q., Yuan, Z., Ma, Y., Su, T., Li, X., Wu, C., Li, D., & Yang, B. (2023). Efficacy and Safety of Neuromodulation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis. *Journal of Affective Disorders*, *334*, 140-150.
* Drosos, A. A., Kalaitzakis, M., Stefanakis, M., Paspaliaris, M. T., Vasileiadis, T., Papageorgiou, C., & Roussos, P. (2023). Ketamine and Esketamine in Treatment-Resistant Depression. *Psychiatria Danubina*, *35*(Suppl 1), 60-66.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.